Canopy Growth News: cannabis task force advisor joins as new CMO, NYSE listing, and more

The vice chair of the federal task force on cannabis legalization is now an executive of Canopy Growth Corp. as the company looks to expand its medical research division amidst its recent listing on the New York Stock Exchange.

Dr. Marc Ware is joining as Chief Medical Officer, and his goal is to develop cannabis research across the globe, saying,

This approach is needed to more effectively respond to the needs of patients and health care professionals worldwide”.

Dr. Ware will be taking a leave of absence from his position as an associate professor of family medicine and anesthesia at McGill University, where he has spent decades studying the medical applications of cannabis for pain management. He will join the company team officially on July 1st, and he will also help build Canopy’s global medical brand, Spectrum Cannabis.

“Bringing Dr. Mark Ware into a senior position within Canopy Growth demonstrates our commitment to building a well-funded, carefully refined global clinical research plan to develop new evidence, markets and products as it related to cannabis,” said Bruce Linton, Chairman & CEO, Canopy Growth.

Other Canopy Growth Corp. news

Last week, on May 24th, Canopy began trading on the NewYork Stock Exchange, and since it’s already listed on the Toronto Stock Exchange, that means it now has two tickers- TSX:WEED and NYSE:CGC.

It was also recently announced that the company is acquiring Canopy Health Innovations, its research arm, and it is safe to assume that their new Chief Medical Officer will be involved in that as well.

Featured image courtesy of


Newswire: Dr. Mark Ware Joins Canopy Growth Corporation as Chief Medical Officer.

Ottawa Citizen: Vice-chair of task force on legalizing pot takes lead research post with Canopy Growth.

Canopy Growth Corp.: Canopy Growth Corp. announces inaugural trading date on the New York Stock Exchange.